ActRIIB Antagonists Increase Adiponectin Levels
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Low levels of adiponectin, known as hypoadiponectinemia, are associated with increased risk of cardiovascular disease and type 2 diabetes, and existing treatments are inadequate in addressing this condition effectively.
Innovation Solution
The use of ActRIIB-derived agents, such as soluble ActRIIB polypeptides and fusion proteins, to inhibit the ActRIIB signaling pathway, thereby increasing adiponectin levels by binding to ActRIIB ligands like myostatin and activins, which regulate adiponectin expression and secretion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If ActRIIB signaling pathway is inhibited using soluble ActRIIB polypeptides, then adiponectin levels increase, but device complexity and treatment cost increase
Solution Approach 1:
The patent uses soluble ActRIIB polypeptides as intermediary molecules that bind to ActRIIB ligands (myostatin, activins, BMPs) and prevent them from interacting with cell surface ActRIIB receptors. This intermediary approach increases adiponectin levels by blocking the inhibitory signaling pathway without requiring direct manipulation of adiponectin production mechanisms, thereby resolving the technical contradiction between achieving therapeutic effect and maintaining treatment simplicity
2Quantity of substance
If ActRIIB ligands like myostatin and activins are blocked, then adiponectin secretion increases, but loss of substance occurs through binding of therapeutic agents to ligands
Solution Approach 1:
The patent extracts and neutralizes the harmful signaling molecules (ActRIIB ligands such as myostatin and activins) by having soluble ActRIIB polypeptides bind to them. This removes the inhibitory signal blocking adiponectin secretion while the soluble polypeptides act as disposable sinks that can be administered at controlled doses, addressing the contradiction between increasing adiponectin secretion and managing therapeutic agent consumption
3Reliability
If soluble ActRIIB polypeptides are administered to increase adiponectin, then cardiovascular disease risk decreases, but manufacturing cost and ease of manufacture worsen
Solution Approach 1:
The patent creates soluble copies of the ActRIIB receptor extracellular domain that can be produced recombinantly in cell cultures. These copied receptor domains are fused to Fc regions or other stabilizing elements to create therapeutically effective molecules that can be manufactured using established biopharmaceutical production methods, thereby resolving the contradiction between providing reliable cardiovascular protection and maintaining manufacturing feasibility
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively increases adiponectin levels, providing protective effects against cardiovascular disease and diabetes by counterbalancing the detrimental actions of proinflammatory adipokines, thereby improving metabolic and cardiovascular health.
Implementation Method 1
ActRIIB-derived agents, such as soluble ActRIIB polypeptides and fusion proteins, to inhibit the ActRIIB signaling pathway, thereby increasing adiponectin levels by binding to ActRIIB ligands like myostatin and activins
Data Source
AI summary
In certain aspects, the present invention provides compositions and methods for increasing adiponectin in a patient in need thereof by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-activin A and/or B antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, and anti-BMP7 antibodies. Also provided are methods for ameliorating one or more undesired effects of anti-androgen therapy, including muscle loss, bone loss, increased adiposity, and/or increased insulin resistance. A variety of disorders may be treated by causing an increase in circulating adiponectin concentrations.